Morphic to present at the 42nd annual j.p. morgan healthcare conference

-dr. praveen tipirneni, returns in full capacity as chief executive officer from medical leave- waltham, mass., jan. 03, 2024 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that praveen tipirneni, m.d.
MORF Ratings Summary
MORF Quant Ranking